(Q35172628)

6 August 2017

1 reference

title

Vaccines for the prevention of neglected diseases--dengue fever (English)

1 reference

6 August 2017

0 references

Tikki Pang

1

1 reference

6 August 2017

1 June 2003

1 reference

Current Opinion in Biotechnology

6 August 2017

1 reference

6 August 2017

14

1 reference

6 August 2017

3

1 reference

6 August 2017

332-336

1 reference

Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Dengue: an escalating problem

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Dengue virus: break-bone fever

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

1 reference

7 January 2021

The future of dengue vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Development of new vaccines against dengue fever and Japanese encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Immune response to synthetic peptides of dengue prM protein

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Spatial and temporal circulation of dengue virus serotypes: a prospective study of primary school children in Kamphaeng Phet, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Control of aedes vectors of dengue in three provinces of Vietnam by use of Mesocyclops (Copepoda) and community-based methods validated by entomologic, clinical, and serological surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

American Genotype Structures Decrease Dengue Virus Output from Human Monocytes and Dendritic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2803%2900061-2

7 January 2021

10.1016/S0958-1669(03)00061-2

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12849789